Related Experiment Video
Updated: Jun 12, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Unveiling the Complexities of Pediatric Asthma Treatment: Evidence, Controversies, and Emerging Approaches
Maria Elisa Di Cicco1, Diego Peroni1, Gian Luigi Marseglia2,3
1Section of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Insights
Pediatric asthma management faces challenges despite inhaled corticosteroids (ICS) and novel biologics. Optimizing treatment requires addressing adherence, age-specific evidence, and personalized strategies for better outcomes.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
- Immunology
Background:
- Pediatric asthma is a global health challenge impacting quality of life and healthcare systems.
- Current management relies on inhaled corticosteroids (ICS), but controversies persist regarding optimal dosing and adherence.
- Novel biologic therapies offer personalized treatment for severe cases but face cost and data limitations.
Purpose of the Study:
- To critically review current pharmacological strategies for pediatric asthma.
- To identify and discuss unresolved issues and evolving approaches in pediatric asthma management.
- To emphasize the need for personalized, evidence-based care tailored to pediatric populations.
Main Methods:
- Literature review of current pharmacological treatments for pediatric asthma.
- Analysis of controversies surrounding inhaled corticosteroids (ICS) and biologic therapies.
- Examination of adherence strategies and the need for age-specific evidence.
Main Results:
- Inhaled corticosteroids (ICS) are effective, with growth suppression linked mainly to high doses.
- Maintenance and Reliever Therapy (MART) shows promise but requires more pediatric data.
- Biologics offer personalized treatment but have high costs and limited long-term data.
Conclusions:
- Optimizing pediatric asthma care requires balancing efficacy with minimal adverse effects.
- Addressing adherence issues and generating age-specific evidence are crucial.
- Personalized, evidence-based strategies are essential for improving treatment outcomes.
Abstract:
Pediatric asthma remains a prevalent and challenging chronic condition globally, affecting quality of life and imposing significant burdens on families and healthcare systems. Despite advancements in understanding asthma pathophysiology and treatment, key controversies persist in optimizing management strategies. Inhaled corticosteroids (ICS) are the cornerstone of treatment, reducing inflammation and preventing exacerbations. While concerns about growth suppression exist, evidence suggests that this effect is primarily associated with high doses and prolonged use, rather than standard maintenance therapy. Nonetheless, adherence to ICS remains suboptimal, necessitating strategies to ensure effective and sustained treatment. The introduction of maintenance and reliever therapy (MART) with ICS-formoterol has offered improved outcomes by simplifying regimens and reducing reliance on short-acting beta-agonists (SABA). However, evidence supporting MART and ICS-SABA regimens in younger children is limited, highlighting gaps in pediatric-focused research. Biologics targeting inflammatory pathways, such as omalizumab, mepolizumab, and dupilumab, represent a personalized approach for severe asthma but face challenges including high costs, limited long-term safety data, and uncertainty regarding their ability to modify disease progression. In addition, the complexity of treatment decisions is compounded by insufficient biomarkers and age-specific evidence to guide therapy. Addressing these gaps requires robust clinical studies and improved adherence strategies tailored to pediatric populations. This review critically examines current pharmacological strategies, unresolved issues, and evolving approaches in asthma management, emphasizing the need for personalized and evidence-based care. Enhancing treatment outcomes for pediatric asthma necessitates balancing therapeutic benefits with minimal adverse effects and leveraging ongoing research to inform future practice.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management
First, in...
